Perha Pharmaceuticals is a biotechnology company focused on the research and development of kinase inhibitors to target specific signaling pathways involved in various diseases. Their work aims to provide effective therapeutic options for conditions such as cancer and inflammatory disorders, addressing the need for more precise treatment modalities.
Funding
$4.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FJFounders
Product
Problem
Many diseases, including cancer and inflammatory disorders, involve dysregulation of kinase signaling pathways. Current treatments often lack the precision needed to selectively target these pathways, leading to off-target effects and limited efficacy. There is a need for more specific therapeutic options that can modulate kinase activity with greater accuracy.
Solution
Perha Pharmaceuticals is developing a portfolio of highly selective kinase inhibitors designed to target specific signaling pathways implicated in various diseases. By focusing on precision, Perha aims to create therapies that minimize off-target effects and maximize therapeutic benefit. Their research and development efforts are centered on identifying and validating novel kinase targets, as well as optimizing the design of small-molecule inhibitors with improved selectivity and potency. This approach seeks to provide more effective and tolerable treatment options for patients with cancer and inflammatory disorders.
Target Audience
Perha Pharmaceuticals' primary customers are pharmaceutical companies seeking to license or acquire novel kinase inhibitors for further development and commercialization, as well as patients with cancer and inflammatory disorders who may benefit from more targeted therapies.
Features
- Discovery and validation of novel kinase targets relevant to disease pathogenesis
- Structure-based drug design to optimize inhibitor selectivity and potency
- Preclinical evaluation of kinase inhibitors in cell-based and animal models
- Development of proprietary assays for measuring kinase activity and inhibitor efficacy
- Formulation and delivery strategies to enhance drug bioavailability and target tissue exposure